Sanofi S.A. Revenue in 2025

Sanofi S.A. reported $45.9B in revenue for fiscal year 2025. This represents a growth of 3% compared to the 2024 figure of $44.6B.

Dupixent's $14.3 billion in FY2024 sales exceeded the total annual revenue of most mid-cap pharmaceutical companies — generated by a single drug that Sanofi co-developed with Regeneron under a collaboration structure initiated in 2007. The Q3 2025 quarterly milestone of $4 billion in global Dupixent sales (and $3 billion in US quarterly sales) for the first time demonstrates the drug's continued growth trajectory even at significant scale. Total revenue grew from $40.8 billion in 2023 to $44.6 billion in 2024, with 2025 projected at $45.9 billion — growth driven primarily by Dupixent expansion as the drug adds patients across its seven approved indications. Net income of $6.2 billion on $44.6 billion in FY2024 revenue produces a 13.9 percent net margin, below the pharmaceutical industry's top-quartile margins because the heavy R&D investment and collaboration profit-sharing with Regeneron reduce the economic return that appears in Sanofi's own income statement. FY2024 R&D expenses reached $8.1 billion — a 14.6 percent increase from 2023 and the company's largest annual R&D investment in history. That urgency reflects the central financial vulnerability: $14.3 billion in Dupixent sales in a portfolio of $44.6 billion means the pipeline must produce significant revenue before Dupixent faces biosimilar competition, which becomes possible as patent protection periods expire in key markets. The Opella separation removes $4.9 billion in consumer healthcare revenue and is projected to drive operating margins toward 32 percent for the remaining pure-play biopharma entity. A 32 percent operating margin on the post-separation revenue base, combined with Dupixent's growth trajectory and the Blueprint Medicines pipeline, represents the financial argument for Sanofi's transformation from diversified pharmaceutical company to focused biopharma.